From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
Both nations deepen cooperation in health innovation, AI-driven healthcare, biomedical research, data sharing, and life sciences to accelerate next-generation healthcare solutions
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
We are building the bridge between complex molecular data and everyday clinical decisions
Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
